Clinical Trial Update: Avelumab and M1774 in ARID1A-mutated Endometrial Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Avelumab in combination with M1774 for ARID1A-mutated endometrial cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• Avelumab (avelumab)
• M1774

Snippet

Sponsor: Panagiotis Konstantinopoulos, MD, PhD | Conditions: Endometrial Cancer, ARID1A Gene Mutation | Phase 2 | Status: RECRUITING